All In Biotech

NDA 213593 · Azurity

Konvomep

Omeprazole, Sodium Bicarbonate · Oral

Last checked: Nov 19, 2026Latest source record: Aug 30, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Aug 30, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

988

158 Phase 3, 48 recruiting

FAERS reports

699

301 serious, 37 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 16, 2025.

KONVOMEP is indicated in adults for: short-term treatment (4 to 8 weeks) of active benign gastric ulcer. reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients. KONVOMEP is a combination of omeprazole, a proton pump inhibitor (PPI) and sodium bicarbonate, indicated in adults for: •Treatment of active benign gastric ulcer ( 1 ) •Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill patients ( 1 )

Mechanism: Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • KONVOMEP · OMEPRAZOLE 2MG/ML; SODIUM BICARBONATE 84MG/ML · FOR SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Omeprazole" as an intervention, any sponsor and status, largest first.

All 988 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease108
  • drug ineffective81
  • acute kidney injury50
  • renal failure44
  • incorrect product administration duration41
  • nausea34
  • product use issue33
  • headache29
  • inappropriate schedule of product administration26
  • death25
  • off label use25
  • diarrhoea24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20103
20111
20142
20155
201612
201725
201862
2019140
2020106
202154
202254
202338
202475
202578
202643

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Konvomep (Omeprazole/Sodium Bicarbonate)

2024 spending

$4.5M

Beneficiaries

1,959

10,159 claims

Per beneficiary

$2,280

$1.41 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$1,917,158
2024$4,466,882

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,390 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.